PEARL
Evidence reviewed
Weekly compounded rapamycin did not show a primary visceral-fat advantage over placebo in PEARL's 114 completers.
Boundary: The 129-person enrollment flow remains unresolved; secondary signals are exploratory.
LongevityNext / Trials
All trial records
Source-reviewed evidence, findings and limitations. Research intelligence, not treatment recommendations.
34 eligible records
BELIEVE
Evidence reviewed
BELIEVE tested bimagrumab and semaglutide alone and together; the higher-dose combination had greater nominal week-48 weight loss.
Boundary: No multiplicity adjustment; semaglutide was open-label, and the extension is separate.
Bimagrumab obesity/T2D trial
Evidence reviewed
Bimagrumab reduced fat mass and increased lean mass versus placebo in adults with type 2 diabetes and obesity.
Boundary: Small trial with attrition; lean mass is not strength, and corrected values control.
Dasatinib plus quercetin diabetic kidney disease pilot
Evidence reviewed
A brief dasatinib-plus-quercetin pilot in diabetic kidney disease reported limited tissue-specific findings.
Boundary: Small uncontrolled study; corrections constrain skin and adipose interpretation.
NICE
Evidence reviewed
NICE tested nicotinamide riboside, alone or with resveratrol, for walking distance in peripheral artery disease.
Boundary: The walking signal met a liberal one-sided threshold and needs confirmation.
NR in obese insulin-resistant men / NCT02303483
Evidence reviewed
Nicotinamide riboside did not improve insulin sensitivity in a 12-week placebo-controlled trial of 40 obese insulin-resistant men.
Boundary: Abstract-level review; the muscle report is the same trial, not replication.
MASTERS
Evidence reviewed
Metformin was associated with smaller muscle gains during MASTERS resistance training; the powered fiber endpoint was not significant.
Boundary: Strength trends and a nonrandomized statin reanalysis do not establish harm or combination benefit.
MMPOWER-3
Evidence reviewed
MMPOWER-3 did not meet its walking or fatigue primary endpoints for elamipretide at 24 weeks.
Boundary: Later genotype-specific findings are exploratory analyses of the same trial.
TAME: Trial Design, Endpoints, and Status Tracker
Evidence reviewed
Tracks TAME's proposed design, composite endpoint, funding, registration and launch status without treating plans as results.
Boundary: Design and status are not results; metformin is not established as an anti-aging treatment.
Metformin in Longevity Study (MILES)
Evidence reviewed
A small randomized crossover mechanistic study in older adults with impaired glucose tolerance.
Boundary: Not clinical longevity-outcome, treatment, prevention or dosing evidence.